Douglas Fambrough insider trades: Dicerna Pharmaceuticals (DRNA) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Douglas reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 10, 2021 | DRNA | ↑ Buy | 5,000 | $22.10 | $110K | Direct | Aug 10, 2021 (0d) |
| Sep 1, 2020 | DRNA | ↑ Buy | 10,000 | $18.06 | $181K | Direct | Sep 1, 2020 (0d) |
| Dec 18, 2019 | DRNA | ↓ Sell | 139,021 | $26.00 | $3.6M | Direct | Dec 19, 2019 (1d) |
| Nov 15, 2016 | DRNA | ↑ Buy | 33,100 | $3.71 | $123K | Direct | Nov 16, 2016 (1d) |
| Jan 29, 2014 | DRNA | ↑ Buy | 5,000 | $15.00 | $75K | Direct | Feb 20, 2014 (22d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Douglas Fambrough's insider trades
Douglas Fambrough is Chief Executive Officer at Dicerna Pharmaceuticals (DRNA). Since Jan 29, 2014, Douglas has reported 4 open-market purchases worth $489K and 1 sale worth $3.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (15 filings), option exercises (6 filings), shares returned to the company (2 filings), shares withheld for taxes (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DRNA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.